Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19

Aim      To evaluate the clinical picture and factors associated with unfavorable outcomes in admitted patients with COVID-19.

Material and methods This study included all patients admitted to the COVID Center of the National Research Center of Cardiology of the Russian Ministry of Health Care from May 1 through May 31, 2020. Clinical demographic, laboratory, and instrumental indexes and associated factors were studied with one-way and multivariate logistic regression analysis.

Results This study included 402 patients aged 18 to 95 years (mean age, 62.9±14.6 years); 43.0 % of them were older than 65 years. COVID-19 was frequently associated with chronic comorbidities, including arterial hypertension (74.4 %), obesity (41.6 %), history of ischemic heart disease (12.9 %), atrial fibrillation (18.9 %), type 2 diabetes mellitus (DM) (13.0 %), and oncological diseases (9.2 %). 13.0 % of patients were smokers; less than 10% had chronic lung diseases. 3.9% of patients had a combination of COVID-19 and acute coronary pathology, including acute myocardial infarction (MI) in 3.2 % (13) and unstable angina in 0.7 % (3). The most frequent clinical manifestation of COVID-19 were four symptoms: cough (81.1 %), weakness (80.3 %), shortness of breath (71.6 %), and fever (62.7 %). 46.5% of patients had shortage of breath and chest pain/compression, 40.3% had headache, 31.1% had myalgia, 28.8% had anosmia, and 25.5% had ageusia. Arterial oxygen saturation was <93.0 % in 55.7 % of cases. According to laboratory blood tests the patients had anemia (58.2 %), lymphopenia (34.8 %), neutropenia (19.2 %), thrombocytopenia (11.9 %), and increased levels of high-sensitivity C-reactive protein (hsCRP, 87.3 %), interleukin-6 (89.3 %), ferritin (62.1 %), and D-dimer (49.2 %). 56.2% of patients required various regimens of oxygen support. 83 (20.6%) patients were admitted to intensive care and resuscitation units; invasive artificial ventilation was performed only for 34 (8.5 %) patients. In-hospital mortality was 7.7 % (31 / 402). One-way regression analysis identified major factors associated with death during the stay in the hospital: age >55 years, NEWS scale score >4.0, oxygen saturation <92.0 %, blood glucose >5.4 mmol/l, hs-CRP >25.7 mg/l, and creatinine clearance <72.0 ml/min. Furthermore, the risk increased with increasing degree of changes in each factor. According to results of the multivariate regression analysis, three most significant predictors of the hard endpoint, all-cause death during the stay in the hospital, were more than 5-fold increases in aspartate aminotransferase and/or alanine aminotransferase compared to normal levels (relative risk (RR) 16.8 at 95 % confidence interval (CI) 5.0–56.3, р<0.001), pronounced changes in the lungs consistent with a CT-4 picture as shown by computed tomography (CT) (RR 13.4; 95 % CI 3.9–45.5, р<0.001), and MI/unstable angina during the stay in the hospital (RR 11.3; 95 % CI 1.4–90.6, р=0.023). The probability of death was also considerably increased by chronic obstructive pulmonary disease, impaired kidney function (creatinine clearance estimated by Cockcroft-Gault <60.0 ml/min), type 2 DM, oncological diseases, and dementia.

Conclusion      This study established factors associated with unfavorable outcomes in admitted patients with COVID-19. This will allow identifying in advance patients with a high risk of complications that require increased attention to take more active diagnostic and therapeutic measures at prehospital and hospital stages.

1. World Health Organisation. Pneumonia of unknown cause – China. [Internet] Available at: http://www.who.int/csr/don/05-january2020-pneumonia-of-unkown-cause-china/en/

2. World Health Organisation. Archived: WHO Timeline – COVID-19. [Internet] Available at: https://www.who.int/news/item/27-04- 2020-who-timeline---covid-19

3. National Institute of Allergy and Infectious Diseases. COVID-19, MERS & SARS. [Internet] Available at: https://www.niaid.nih.gov/diseases-conditions/covid-19

4. World Health Organisation. Weekly epidemiological update - 1 December 2020. [Internet] Available at: https://www.who.int/publications/m/ item/weekly-epidemiological-update---1-december-2020

5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5

6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. DOI: 10.1001/jama.2020.2648

7. National Institute of Health. Coronavirus Disease 2019 (COVID-19). Treatment Guidelines. Information on COVID-19 Treatment, Prevention and Research. [Internet] Available at: https://www.covid19treatmentguidelines.nih.gov/

8. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 6 (28.04.2020). Av. at: https://стопкоронавирус.рф/ai/doc/194/attach/28042020_mR_COVID-19_v6.pdf. 2020.

9. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 9 (26.10.2020). Av. at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/ original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062. 2020.

10. Government of the Russian Federation. Reports of the Communication Center of the Government of the Russian Federation on the situation with coronavirus. Av. at: https://стопкоронавирус.рф/info/ofdoc/reports/. 2020.

11. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730–41. DOI: 10.1111/all.14238

12. Paranjpe I, Russak AJ, De Freitas JK, Lala A, Miotto R, Vaid A et al. Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.04.1 9.20062117. [DOI: 10.1101/2020.04.19.20062117]. 2020.

13. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–9. DOI: 10.1001/jama.2020.6775

14. Oh S-J, Lee JK, Shin OS. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Network. 2019;19(6):e37. DOI: 10.4110/in.2019.19.e37

15. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6. DOI: 10.1038/s41586-020-2521-4

16. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;94:91–5. DOI: 10.1016/j.ijid.2020.03.017

17. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020;109(5):531–8. DOI: 10.1007/s00392-020-01626-9

18. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology. 2020;14(4):813–21. DOI: 10.1177/1932296820924469

19. Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Family Medicine and Community Health. 2020;8(2):e000406. DOI: 10.1136/fmch-2020-000406

20. Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clinical Immunology. 2020;217:108509. DOI: 10.1016/j.clim.2020.108509

21. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13. DOI: 10.1016/S0140-6736(20)30211-7

22. Liang W, Liang H, Ou L, Chen B, Chen A, Li C et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Internal Medicine. 2020;180(8):1081–9. DOI: 10.1001/jamainternmed.2020.2033

23. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. DOI: 10.1136/bmj.m1966

24. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clinical Microbiology and Infection. 2020;26(11):1525–36. DOI: 10.1016/j.cmi.2020.07.024

25. Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B et al. COVID-19 mortality risk assessment: An international multi-center study. PLOS ONE. 2020;15(12):e0243262. DOI: 10.1371/journal.pone.0243262

26. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH et al. Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis. Journal of Medical Virology. 2020;92(10):1875–83. DOI: 10.1002/jmv.26050